Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

BACKGROUND AND OBJECTIVES The aim of our study was to examine serum markers of the TNF and Fas pathways for association with cystatin-C based estimated glomerular filtration rate (cC-GFR) in subjects with type 1 diabetes (T1DM) and no proteinuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS The study group (the 2nd Joslin Kidney Study) comprised patients with T1DM and normoalbuminuria (NA) (n = 363) or microalbuminuria (MA) (n = 304). Impaired renal function (cC-GFR <90 ml/min) was present in only 10% of patients with NA and 36% of those with MA. We measured markers of the tumor necrosis factor alpha (TNFalpha) pathway [TNFalpha, soluble TNF receptor 1 (sTNFR1), and 2 (sTNFR2)], its downstream effectors [soluble intercellular and soluble vascular adhesion molecules (sICAM-1 and sVCAM-1), interleukin 8 (IL8/CXCL8), monocytes chemoattractant protein-1 (MCP1), and IFNgamma inducible protein-10 (IP10/CXCL10)], the Fas pathway [soluble Fas (sFas) and Fas ligand (sFasL)], CRP, and IL6. RESULTS Of these, TNFalpha, sTNFRs, sFas, sICAM-1, and sIP10 were associated with cC-GFR. However, only the TNF receptors and sFas were associated with cC-GFR in multivariate analysis. Variation in the concentration of the TNF receptors had a much stronger impact on GFR than clinical covariates such as age and albumin excretion. CONCLUSIONS Elevated concentrations of serum markers of the TNFalpha and Fas-pathways are strongly associated with decreased renal function in nonproteinuric type 1 diabetic patients. These effects are independent of those of urinary albumin excretion. Follow-up studies are needed to characterize the role of these markers in early progressive renal function decline.

[1]  A. Krolewski,et al.  High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[2]  C. López-Aguilar,et al.  Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  Y. Li,et al.  Role of ADAM17 in the ectodomain shedding of TNF‐α and its receptors by neutrophils and macrophages , 2007, Journal of leukocyte biology.

[4]  L. Cupples,et al.  Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[5]  J. Chan,et al.  Aberrant activation profile of cytokines and mitogen‐activated protein kinases in type 2 diabetic patients with nephropathy , 2007, Clinical and experimental immunology.

[6]  R. MacIsaac,et al.  The accuracy of cystatin C and commonly used creatinine‐based methods for detecting moderate and mild chronic kidney disease in diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[7]  A. Melidonis,et al.  Correlation between Increased Serum sFas Levels and Microalbuminuria in Type 1 Diabetic Patients , 2007, Medical Principles and Practice.

[8]  J. Weinberg,et al.  Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. , 2007, Journal of the American Society of Nephrology : JASN.

[9]  S. Cummings,et al.  Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. , 2007, Kidney international.

[10]  J. Navarro,et al.  The role of TNF-α in diabetic nephropathy: Pathogenic and therapeutic implications , 2006 .

[11]  E. Rimm,et al.  The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. , 2006, Kidney international.

[12]  J. Navarro,et al.  Role of inflammation in diabetic complications. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  A. Jenkins,et al.  Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  P. Vandenabeele,et al.  TNFR1‐ and TNFR2‐mediated signaling pathways in human kidney are cell type‐specific and differentially contribute to renal injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  P. Gottschalk,et al.  The five-parameter logistic: a characterization and comparison with the four-parameter logistic. , 2005, Analytical biochemistry.

[16]  M. Pfeffer,et al.  Biomarkers of inflammation and progression of chronic kidney disease. , 2005, Kidney international.

[17]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[18]  N. Chaturvedi,et al.  Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study , 2005, Diabetologia.

[19]  J. Manson,et al.  Kidney dysfunction, inflammation, and coronary events: a prospective study. , 2004, Journal of the American Society of Nephrology : JASN.

[20]  M. Takemura,et al.  Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings , 2004, Nephrology.

[21]  K. Burns,et al.  Evidence of apoptosis in human diabetic kidney , 2004, Molecular and Cellular Biochemistry.

[22]  K. Burns,et al.  Tubular and Interstitial Cell Apoptosis in the Streptozotocin-Diabetic Rat Kidney , 2004, Nephron Experimental Nephrology.

[23]  M. Mauer,et al.  Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. , 2003, Diabetes.

[24]  D. MacEwan.  TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[25]  J. Tschopp,et al.  Regulation of Fas Ligand-Induced Apoptosis by TNF1 , 2001, The Journal of Immunology.

[26]  G. Zoppini,et al.  Elevated Plasma Levels of Soluble Receptors of TNF-α and Their Association with Smoking and Microvascular Complications in Young Adults with Type 1 Diabetes , 2001 .

[27]  B. Jaber,et al.  Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. , 2000, The Journal of laboratory and clinical medicine.

[28]  A. Ortiz,et al.  Nephrology Dialysis Transplantation the Fas Ligand/fas System in Renal Injury Fasl and Fas Leukocytes and Intrinsic Renal Cells ( Table 1). Murine , 2022 .

[29]  J. Fahey,et al.  Levels of Cytokines and Immune Activation Markers in Plasma in Human Immunodeficiency Virus Infection: Quality Control Procedures , 1998, Clinical Diagnostic Laboratory Immunology.

[30]  J. Schelling,et al.  Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[31]  A. Cope,et al.  Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. , 1998, The Journal of clinical investigation.

[32]  A. Krolewski,et al.  Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[33]  J. Camonis,et al.  Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.

[34]  D. Gouma,et al.  Tissue distribution and clearance of soluble murine TNF receptors in mice. , 1994, Cytokine.

[35]  M. Brockhaus,et al.  Plasma tumor necrosis factor soluble receptors in chronic renal failure. , 1992, Kidney international.

[36]  K. Ley,et al.  Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[37]  J. Navarro,et al.  The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. , 2006, Cytokine & growth factor reviews.

[38]  G. Zoppini,et al.  Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[39]  S. Segerer,et al.  Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. , 2000, Journal of the American Society of Nephrology : JASN.